Clinical Study Team
Prof. Dr. Josef Priller
Director, Department of Neuropsychiatry & Vice Chair, Department of Psychiatry and Psychotherapy CCM Charité – Universitätsmedizin Berlin
c/o Charité – Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin

josef.priller@dzne.de
 +49 30 450 517-209

Areas of investigation/research focus

Neurodegenerative diseases are incurable conditions that result in neuronal dysfunction and cell death. The immune system plays an important role in central nervous system (CNS) homeostasis and impaired immune function may contribute to neurodegenerative diseases. In particular, misguided activation of microglia, the resident tissue macrophages of the CNS, may disturb neural function and promote degeneration.   

The interdisciplinary team led by Josef Priller consists of neurologists, psychiatrists and neuropsychologists who share an interest in neurodegenerative diseases, in particular Alzheimer’s disease (AD), Huntington’s disease (HD) and frontotemporal lobar degeneration (FTLD). The team has been successfully conducting industry-sponsored phase 1 to phase 3 studies and has coordinated investigator-initiated trials into potential neuroprotective drugs, such as green tea ECGC. Drawing on a longstanding expertise in neuropsychiatry, the team has been investigating behavioural and psychological symptoms of dementia and was instrumental in formulating clinical guidelines.

In order to study mechanisms of disease, the laboratory team has been immunophenotyping myeloid cells from blood and CNS using state-of-the-art techniques like RNA sequencing and mass cytometry. In a translational approach, repurposing of licensed drugs that modulate the proteostasis network has been explored in preclinical models of disease. Moreover, patient-derived pluripotent stem cells have been generated in order to study the effects of genetic and environmental disturbances on the pathogenesis of neurodegenerative diseases and to screen for potential disease-modifying drugs.

 more Infos

DELCODE

As one of the major clinical centers contributing to this longitudinal study on cognitive impairment and dementia, we have been seeking to improve the detection of the early disease stages of AD. In a substudy, we have been trying to correlate olfactory function with cognitive measures and hippocampal volume in patients with subjective cognitive decline, mild cognitive impairment and AD. In another substudy, we have been exploring the role of myeloid cells in AD and the potential to use bioenergetic dysfunction of mononuclear cells as a biomarker of disease progression in AD and FTLD.

DESCRIBE-FTD

In this longitudinal study on behavioural variant frontotemporal dementia and primary progressive aphasias, we have been trying to provide a better understanding of the pathogenesis and the disease course of FTLD.

 

Key Publications

Prinz M, Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci. 2014 Jan 01; 15:300-12. doi: 10.1038/nrn3722
Fernández-Klett F, Offenhauser N, Dirnagl U, Priller J*, Lindauer U*. Pericytes in capillaries are contractile in vivo, but arterioles mediate functional hyperemia in the mouse brain. Proc Natl Acad Sci USA. 2010 Jan 01; 107:22290-5. doi: 10.1073/pnas.1011321108
Mildner A, Schmidt H, Nitsche M, Merkler D, ... , Priller J *, Prinz M*. Microglia in the adult brain arise from Ly -6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci. 2007 Jan 01; 10:1544-53. doi: 10.1038/nn2015
Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, ... , Priller J , et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002 Jan 01; 8:831-40. doi: 10.1038/nm731
Priller J, Flügel A, Wehner T, Boentert M, Haas CA, Prinz M, et al. Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat Med. 2001 Jan 01; 7:1356-61. doi: 10.1038/nm1201 -1356

Info-Hotline

Thursdays 1:30-4:30 pm

Patients +49 800-7799001

(free of charge)

Professionals +49 180-779900

(9 Cent/Min. German landline, mobile and out of Germany possibly more expensive)

Inform yourself on our website cookie-free. However, we would be pleased if you would allow us to use statistical cookies. Your browser settings regarding cookies are currently as follows:
More information can be found in our Privacy policy.